NASDAQ$ORIC
ORIC Pharmaceuticals Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Discontinued development of ORIC-101 and focused on advancing three single agent Phase 1 programs.
ORIC Pharmaceuticals discontinued the development of ORIC-101 after interim analyses showed insufficient clinical activity. The company will now focus on advancing its three single agent Phase 1 programs and expects to report initial data in the first half of 2023. With cash and investments of $280.4 million, the company's cash runway is extended into the second half of 2024.
- ORIC Pharmaceuticals discontinued development of ORIC-101 due to insufficient clinical activity in Phase 1b studies.
- The company will focus on advancing ORIC-533, ORIC-114, and ORIC-944, with initial data expected in 1H 2023.
- ORIC-114 Clinical Trial Application was filed in Q4 2021 and cleared by the regulatory authorities of the Republic of Korea in Q1 2022.
- Cash runway is expected to extend into the second half of 2024, with cash and investments totaling $280.4 million as of December 31, 2021.
Headline financials
Revenue & EPS history
ORIC Pharmaceuticals · Revenue · Quarterly
$0
Forward guidance
ORIC anticipates initial Phase 1b data from ORIC-533, ORIC-114, and ORIC-944 in the first half of 2023.
Tailwinds
- ORIC-533: Initial Phase 1b data in 1H 2023
- ORIC-114: Initial Phase 1b data in 1H 2023
- ORIC-944: Initial Phase 1b data in 1H 2023
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.2%
Avg return
Earnings day
+1.1%
Avg return
5 days after
+8.0%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+14.7%
Q2 2023
Best reaction
-29.8%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +14.7% | +14.9% | +5.7% | |
| Q3 2025 | +0.3% | -5.8% | -23.1% | |
| Q2 2025 | -1.0% | -7.9% | +8.9% | |
| Q1 2025 | +8.7% | +25.8% | +98.9% | |
| Q4 2024 | +0.8% | +2.1% | -43.5% | |
| Q3 2024 | -0.3% | -17.5% | -18.2% | |
| Q1 2024 | -1.0% | -7.4% | -5.6% | |
| Q4 2023 | -4.5% | +0.7% | -33.3% | |
| Q3 2023 | -3.2% | -11.9% | +26.4% | |
| Q2 2023 | +14.7% | +13.8% | +17.3% | |
| Q1 2023 | -0.4% | +0.1% | +11.4% | |
| Q4 2022 | +5.3% | +14.8% | +39.5% | |
| Q3 2022 | +2.8% | +17.9% | +35.4% | |
| Q2 2022 | +3.2% | -2.1% | -26.4% | |
| Q1 2022 | -3.4% | -4.4% | +52.0% | |
| Q4 2021 | -29.8% | -33.0% | -42.6% | |
| Q3 2021 | +7.1% | +8.4% | -7.1% | |
| Q2 2021 | +9.4% | +13.6% | +45.2% | |
| Q1 2021 | +2.1% | +6.1% | -17.0% | |
| Q4 2020 | -6.2% | -7.6% | -10.2% | |
| Q3 2020 | +3.8% | +4.4% | +55.6% | |
| Q2 2020 | +12.5% | +12.4% | +7.8% | |
| Q1 2020 | -8.7% | -11.3% | +7.3% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro